Intensive pharmacokinetics of zidovudine 200 mg twice daily in HIV-1-infected patients weighing less than 60 kg on highly active antiretroviral therapy [4]

Journal of Acquired Immune Deficiency Syndromes

Volumn 42, Issue 3, 2006, Pages 387-389

  Cressey, Tim R ^a,b   Leenasirimakul, Prattana ^c   Jourdain, Gonzague ^a,b   Tawon, Yardpiroon ^b   Sukrakanchana, Pra Ornsuda ^b   Lallemant, Marc ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b Institut de Recherche Pour Le Développement IRD   (Thailand)

^c Nakornping Provincial Hospital   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; HEMOGLOBIN; INDINAVIR; LAMIVUDINE; RITONAVIR; ZIDOVUDINE;

ADULT; AREA UNDER THE CURVE; BLOOD SAMPLING; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MALE; MAXIMUM ALLOWABLE CONCENTRATION; MAXIMUM TOLERATED DOSE; PARAMETERS OF MEASUREMENT AND ANALYSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; REPEAT PROCEDURE; THAILAND; UNSPECIFIED SIDE EFFECT; WILCOXON SIGNED RANKS TEST;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AREA UNDER CURVE; DRUG ADMINISTRATION SCHEDULE; HALF-LIFE; HIV INFECTIONS; HUMANS; PRACTICE GUIDELINES; REVERSE TRANSCRIPTASE INHIBITORS; ZIDOVUDINE;

EID: 33745910844     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000221685.90681.1b     Document Type: Letter

References (14)

1. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987;317(4):185-191.
2. Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987;317(4):192-197.
3. Fischl MA, Parker CB, Pettinelli C, et al. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med. 1990;323(15):1009-1014.
4. Shepp DH, Ramirez-Ronda C, Dall L, et al. A comparative trial of zidovudine administered every four versus every twelve hours for the treatment of advanced HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;15(4):283-288.
5. Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents. Department of Health and Human Services (DHHS), NIH, USA; 2005.
6. National Guidelines for the Clinical Management of HIV Infection in Children and Adults. Nonthaburi, Thailand: AIDS Division, Department of Communicable Disease Control, Ministry of Public Health; 2005.
7. Wattanagoon Y, Na Bangchang K, Hoggard PG, et al. Pharmacokinetics of zidovudine phosphorylation in human immunodeficiency virus-positive Thai patients and healthy volunteers. Antimicrob Agents Chemother. 2000;44(7):1986-1989.
8. Burger DM, Meenhorst PL, ten Napel CH, et al. Pharmacokinetic variability of zidovudine in HIV-infected individuals: subgroup analysis and drug interactions. AIDS. 1994;8(12):1683-1689.
9. Sahai J, Gallicano K, Ormsby E, et al. Relationship between body weight, body surface area and serum zidovudine pharmacokinetic parameters in adult, male HIV-infected patients. AIDS. 1994;8(6):793-796.
10. Zhou XJ, Sheiner LB, D'Aquila RT, et al. Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Antimicrob Agents Chemother. 1999;43(1):121-128.
11. Cressey TR, Leenasirimakul P, Jourdain G, et al. Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability. J Antimicrob Chemother. 2005;55(6):1041-1044.
12. Cremieux AC, Katlama C, Gillotin C, et al. A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults. Pharmacothempy. 2001;21(4):424-430.
13. Wang LH, Chittick GE, McDowell JA. Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection. Antimicrob Agents Chemother. 1999;43(7):1708-1715.
14. Vanhove GF, Kastrissios H, Gries JM, et al. Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy. Antimicrob Agents Chemother. 1997;41(11):2428-2432.